Business, energy, technology, markets and global industry news from Business News Today

atherosclerotic cardiovascular disease

PharmaDeviceNews atherosclerotic cardiovascular disease
Representative image: Cardiovascular researchers review heart imaging and trial data as Novo Nordisk’s $NVO ziltivekimab lowers inflammation but fails to reduce heart attacks, strokes or cardiovascular deaths in the Phase 3 ZEUS trial.
Pharma & Biotech

Ziltivekimab lowers inflammation but fails Phase 3 cardiovascular outcomes test

Ziltivekimab lowered IL-6 activity and hsCRP but failed to reduce major cardiovascular events in Novo Nordisk’s 6,300-patient ZEUS trial.

Read More
Representative image showing cardiovascular drug research and epigenetic silencing technology, reflecting Scribe Therapeutics’ STX-1150 strategy for long-lasting LDL-C reduction after a single dose.
Pharma & Biotech

Can Scribe Therapeutics make one-dose LDL-C lowering a practical CRISPR frontier?

Find out how Scribe Therapeutics’ STX-1150 could reshape long-acting LDL-C lowering through CRISPR-based epigenetic silencing.

Read More
Pharma & Biotech

Merck may have solved the hidden problem behind the oral PCSK9 race

Oral PCSK9 drugs need more than strong LDL data. Merck’s enlicitide paper tests whether peptide manufacturing can scale.

Read More
Pharma & Biotech

Can Merck’s enlicitide decanoate become the oral PCSK9 breakthrough cholesterol care has been waiting for?

Merck’s enlicitide decanoate beat oral rivals in Phase 3. Read what this could change for cholesterol care, PCSK9 adoption, and market strategy.

Read More